In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/annonc/mdm216 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!